Antifungal Resistant Dematiaceous Fungal Infections in Humans: Implications and Innovative Solutions
Scientia Africana · 30.03.2026 · 25 (1) · 205-228
DOI: 10.4314/sa.v25i1.16 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Africana, online erschienen am 30.03.2026. Verfasst von E. N. Anaele und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Dematiaceous fungi are diverse group of melanized fungi that cause infections in both immunocompetent and immunocompromised individuals, ranging from superficial to life-threatening systemic infections, including phaeohyphomycosis, chromoblastomycosis, eumycetoma and sometimes onychomycosis. Infections caused by these fungi are increasing due to advances in medical therapy, a rise in predisposing comorbidities such as diabetes, and recognition of virusassociated fungal diseases during the COVID-19 pandemic. The increasing rate of antifungal resistance poses a great challenge to effective treatment as many dematiaceous molds exhibit acquired resistance to available antifungal agents such as azoles and polyenes. Mutations in drugtarget site, melanin mediated drug sequestration, and efflux pump overexpression are among the resistance mechanisms manifested by these fungi often leading to chronic infections. The clinical implications of antifungal resistance in these fungi are significant, as limited therapeutic options result in prolonged morbidity, high mortality, and increased healthcare costs due to disease reoccurrence promoting the need for alternative treatment options. Currently, the emerging innovative approaches to dematiaceous mold infections include surgical intervention and combination of therapy, plant-derived antifungal peptides, photodynamic therapy and use of artificial intelligence (AI) in assisting diagnosis and treatment to advance personalized medicine and improve treatment outcome. As resistance to antifungals continues to grow, proactive and innovative approaches are essential to safeguard public health and ensure the effective management of resistant dematiaceous mold infections.
Zitieren
APA
Anaele, E. N., Amoke, M., & Nweke, R. N. (2026). Antifungal Resistant Dematiaceous Fungal Infections in Humans: Implications and Innovative Solutions. Scientia Africana, 25(1), 205-228. https://doi.org/10.4314/sa.v25i1.16
Vancouver
Anaele EN, Amoke M, Nweke RN. Antifungal Resistant Dematiaceous Fungal Infections in Humans: Implications and Innovative Solutions. Scientia Africana. 2026;25(1):205-228. doi:10.4314/sa.v25i1.16
BibTeX
@article{Anaele2026,
author = {Anaele, E. N. and Amoke, M.C. and Nweke, R. N.},
title = {Antifungal Resistant Dematiaceous Fungal Infections in Humans: Implications and Innovative Solutions},
journal = {Scientia Africana},
year = {2026},
volume = {25},
number = {1},
pages = {205--228},
doi = {10.4314/sa.v25i1.16}
}
EUVIMED